Assorted News from the Last Week: To achieve successful socioeconomic reintegration in the long term, it is crucial to implement a childhood cancer survivorship program

Assorted News from the Last Week: The UK’s National Institute for Health and Care Excellence (NICE) recommended Novartis’ autologous CAR T-cell therapy Kymriah (tisagenlecleucel) for

Assorted News from the Last Week: FDA announced its Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee will meet virtually on 22 May to

Assorted News from the Last Week: Cancer is far more likely to be caused by “tumor-suppressor” genes than by one gene run amok. Interestingly, last

Assorted News from the Last Week: The White House Office of Science and Technology Policy (OSTP) has announced that the Pediatric Cancer Data Commons (PCDC)

Assorted News from the Last Week: Feature story about CAC2 Member Beat Childhood Cancer and new FDA approved therapeutic DFMO: Families of paediatric cancer patients

Assorted News from the Last Week: Cancer Grand Challenges has selected five new global research teams that will address the following challenges in cancer. This

Assorted News from the Last Week: Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada. President’s Cancer Panel Initial Assessment